News and Trends 22 Nov 2017
Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout
Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a range of indications. It partnered up with the global pharma company, AbbVie, back in 2013, to develop a number of cystic fibrosis (CF) candidates for a […]